Abstract This review aims to address significant anomalies and discrepancies that have surfaced from the examination of the data from the Pfizer/BioNTech C4591001 trial, which could have profound implications for public trust and regulatory standards, should they not be adequately and transparently investigated. Whistleblower Testimonies Brook Jackson, a former […]